title: Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system.
abstract: The National Institute for Health and Clinical Excellence recommends vinorelbine (VNB), paclitaxel, docetaxel, and gemcitabine in the treatment of non-small cell lung cancer. An economic model was prepared to determine the comparative cost of these agents, including the new oral formulation of VNB from a United Kingdom National Health System perspective. Clinical effectiveness was determined from published trials. Costs of drug acquisition, administration, toxicity management, and patient transportation costs were calculated from reference publications. A Markov model was used to estimate the cost per patient over 52 weeks. Intravenous VNB, gemcitabine, paclitaxel, and docetaxel incur annual follow-up costs of 3,746 pounds, 5,332 pounds, 5,977 pounds, and 6,766 pounds, respectively, while oral VNB with outpatient administration on d1, and self-administration at home on d8 every 21 days has a cost per patient per year of 2,888 pounds. Oral VNB allows further hospital resources savings.
authors.affiliation: REES France, 28 rue d'Assas, 75 006, Paris, France. reesfrance@wanadoo.fr
authors.forename: K
authors.initials: K
authors.lastname: Le Lay
authors.forename: E
authors.initials: E
authors.lastname: Myon
authors.forename: S
authors.initials: S
authors.lastname: Hill
authors.forename: L
authors.initials: L
authors.lastname: Riou-Franca
authors.forename: D
authors.initials: D
authors.lastname: Scott
authors.forename: M
authors.initials: M
authors.lastname: Sidhu
authors.forename: D
authors.initials: D
authors.lastname: Dunlop
authors.forename: R
authors.initials: R
authors.lastname: Launois
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003365:Costs and Cost Analysis; D004333:Drug Administration Routes; D006699:Home Care Services; D006801:Humans; D007262:Infusions, Intravenous; D013222:State Medicine; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents